Standard chemotherapeutics used to treat HNSCC are represented by cisplatin, 5-fluorouracil, and docetaxel, although currently targeted therapy regimens are also introduced, namely monoclonal antibodies against epithelial growth factor receptor (EGFR)—cetuximab, or programmed death receptor 1 (PD-1)—nivolumab and pembrolizumab [2]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.